KymetaTM Expands Its Next Generation Solutions with Commercial Availability of the u8 GOV Terminal and u8 GO
9.2.2021 17:00:00 EET | Business Wire | Press release
Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced today the expansion and availability of its KymetaTM u8 product, including the Kymeta u8 GOV terminal with an embedded iDirect 950mp modem and the u8 GO transportable terminal. Kymeta u8 GOV terminals are designed to meet the needs of government, military and specialized commercial use and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005134/en/
The u8 GOV terminal and u8 GO provide the complete connectivity solution for on-the-go communications. (Photo: Business Wire)
The u8 GOV terminal includes a FIPS, 140-2 level 3 TRANSEC module and meets the demands of tactical users in scenarios that require secure data, voice, and video connectivity in highly mobile military, government and other rapid response applications. The u8 GOV terminal covers the full Ku-band and is available today as a turnkey terminal with a satellite modem, cellular modem, and SD-WAN capabilities. It is compliant with existing security requirements as defined by the National Institute of Standards and Technology (NIST).
“Kymeta’s solutions meet the mission-critical needs of military, first responders, and commercial customers providing ‘always-on’ connectivity for mobile platforms, making communications on the move more seamless and reliable than ever,” said Rob Weitendorf, Vice President, Business Development, Kymeta.
Also available today, the u8 GO transportable terminals come in multiple configurations including ODU, Commercial and GOV terminals, and enable safe transport with a hardened and rugged shipping case for protection and provide a built-in vehicle mount to support easy communications on the pause (COTP) and communications on-the-move (COTM). This transportable configuration is easily maneuverable and ideal for rapid deployments and has been tested against military transportation standards including MIL-STD-810H, Transit Drop, Transportation Shock, and Loose Cargo Vibration. The u8 GO includes an outdoor AC/DC power supply, supports communications on the pause (COTP) with a 25-degree tilt mechanism, and can also be mounted on a vehicle for easy deployment in a multitude of use cases.
The Kymeta u8 solutions, which now also include the u8 GOV terminal and u8 GO transportable case, provide a complete connectivity solution for communications-on-the-move (COTM) and networks-on-the-move (NOTM) when and where you need it most. The u8 terminal, with Kymeta’s revolutionary software-defined, electronic beam-steering technology, is low profile and easy-to-mount on vehicles and vessels. The u8 turnkey solutions come in multiple terminal configurations that provide customers with the hardware, software, and connectivity they need.
Kymeta recently launched its next-generation antenna, terminal, and services in Q4 of 2020, and has received an overwhelmingly positive response from the industry. The Kymeta u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect™, transforms the purchase and consumption of mobile data with all-inclusive hardware, connectivity, and services monthly subscription. The Kymeta u8 is the world’s only commercially available flat-panel electronically steered antenna built specifically for mobility and designed for the needs of military, first responders, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005134/en/
Contact information
Business Inquiries for Kymeta:
Jon Maron
Vice President of Marketing and Communications
Kymeta Corporation
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Associated Director PR, The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom